UnitedHealth Lifts Low-End of EPS Forecast After Solid Earnings
When UnitedHealth Group reported second-quarter 2016 results before markets opened Tuesday, it also updated its full-year earnings guidance.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 204
What to Look for in Johnson & Johnson Earnings
Johnson & Johnson is set to release its second-quarter earnings report before the markets open on Tuesday, a period in which it agreed to acquire a privately held company focused on hair care and…
4 Speculative Biotech and Biohealth Analysts Calls for Huge Upside
Investors in the biotech and biohealth space generally are taking on much more risk than in the likes of most Dow and S&P 500 stocks. That means they will demand more potential upside for…
Synergy Pharmaceuticals Sinks on FDA Update
Investor reaction to Synergy Pharmaceuticals reaching the FDA mid-cycle review milestone for the plecanatide new drug application in chronic idiopathic constipation was not as positive as the company would have hoped.
Pharmaceutical Stocks May Be the Best Total Return Play: 3 to Buy Now
With yields plunging and the market getting very pricey, some top pharmaceutical stocks are starting to look like a great total return vehicle for the rest of this year and into 2017.
Why Teva’s $20 Billion Bond Sale Makes Sense, as Long as It’s a Fixed Rate
Lucky for Teva Pharmaceuticals, interest rates on all kinds of debt have never been lower in recorded human history, and they keep getting lower even beyond basic logic.
Why the Teva Acquisition Proves It Is a Stock to Own for the Decade
Even though the trend toward generic drugs is only likely to grow, the drug price pressures hanging over the sector also hurt most generic drug makers.
Short Sellers Run for Cover From Major Pharma
The June 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest decreased.
Short Sellers Become More Selective on Major Biotechs
The June 30 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
CytRx Crumbles on Late-Stage Whiff
CytRx absolutely crumbled in Tuesday’s session after the company released less than favorable late-stage results.
Shire Gains Key FDA Approval in Dry Eye Treatment
Shire made waves Tuesday morning following a key FDA approval of its eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients.
Protagonist Therapeutics Files for IPO
Protagonist Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Biotechs With Drug Pipelines Closest to Zero Valuation
Credit Suisse has taken a look at which biotech companies in its coverage have the least credit given to pipeline potential at current levels.
Sage Therapeutics Scores Huge Win in Depression Trial
Sage Therapeutics blew out expectations early on Tuesday morning after the company released results from its mid-stage depression trial.
Is Too Big to Fail Coming to a Health Care Sector Near You?
The fact that major health care mergers were announced at the same time that the Affordable Care Act began to take full effect is no coincidence.